Evidence map›Paper›PMID 27737874›Full record

ArticleJournal of the American Heart Association2016

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol.

Allan D Sniderman, Shofiqul Islam, Matthew McQueen, Michael Pencina, Curt D Furberg, George Thanassoulis, Salim Yusuf

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Evaluation and management of blood lipids through a woman's life cycle.American journal of preventive cardiology · 2022
    Review
  17. Review
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Allan D SnidermanMcGill University, Montreal, Canada allansniderman@hotmail.com.
Shofiqul IslamPopulation Research Institute and McMaster University, Hamilton, Canada.
Matthew McQueenPopulation Research Institute and McMaster University, Hamilton, Canada.
Michael PencinaDuke Clinical Research Institute, Durham, NC.
Curt D FurbergPublic Health Sciences, Wake Forest University, Winston-Salem, NC.
George ThanassoulisMcGill University, Montreal, Canada.
Salim YusufPopulation Research Institute and McMaster University, Hamilton, Canada.
McGill University · CAMcMaster University · CAClinical Research Institute · USPopulation Health Research Institute · CAWake Forest University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigher concentrations of the apolipoprotein B (apoB) lipoproteins increase the risk of cardiovascular disease. However, whether the risk associated with apoB lipoproteins varies with age has not been well examined. METHODS AND

resultsWe determined the associations for total cholesterol, low-density lipoprotein (LDL)-cholesterol (LDL-C), non-high-density lipoprotein-cholesterol (non-HDL-C), apoB, apolipoprotein A-I (apoA-I), and HDL-cholesterol (HDL-C) with myocardial infarction at different ages in 11 760 controls and 8998 myocardial infarction cases of the INTERHEART Study. Logistic regression was used to compute the odds ratio of myocardial infarction for 1 SD change in each lipid marker by decade from <40 to >70 years of age. Except for those >70, plasma levels of total cholesterol, LDL-C, and non-HDL-C and apoB were greater in cases than controls. However, the average levels of these markers decreased significantly as age increased. By contrast, levels of apoA-I and HDL-C were significantly greater in controls than cases but increased significantly as age increased. The cardiovascular risk associated with the atherogenic lipid markers differed at different ages. Most notably, there was a significant decline in the odds ratio for total cholesterol, LDL-C, and non-HDL-C, and apoB with increases in age whereas the odds ratios associated with apoA-I and HDL-C were consistent across the age groups.

conclusionsThese data indicate that the risk of cardiovascular events associated with apoB particles is greater in younger compared to older individuals. This finding is consistent with greater relative benefit from LDL-lowering therapy in younger compared to older individuals and so argues for therapy in younger individuals with elevated lipids.

Indexed as

AdultAgedAge FactorsApolipoprotein A-IApolipoprotein B-100Cardiovascular DiseasesCholesterol, HDLCholesterol, LDLFemaleHumansLogistic ModelsMaleMiddle AgedMyocardial InfarctionOdds RatioAPOB protein, humanApolipoprotein A-IApolipoprotein B-100Cholesterol, HDLCholesterol, LDLapolipoprotein Bcardiovascular eventslow‐density lipoprotein cholesterolnon‐high‐density lipoprotein cholesterolprimary preventionrisk assessmentrisk factorrisk prediction

Identifiers

PMID27737874
PMCPMC5121475
OpenAlexW2531389841

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.